Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Bristol-Myers Squibb (BMS)
Scientific Title
A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma